Fab’entech is launching an immunotherapy programme against COVID-19
Phase I/II clinical trials in humans scheduled in 2021 Polyclonal antibodies are a safe, reproducible solution that is rapidly industrialisable at large scale thanks to Fab’entech’s new industrial site
